Welcome to our dedicated page for Remsleep Holding news (Ticker: RMSL), a resource for investors and traders seeking the latest updates and insights on Remsleep Holding stock.
REMSleep Holdings, Inc. (RMSL) generates news primarily around its development and commercialization of CPAP mask interfaces for obstructive sleep apnea and related respiratory conditions. The company’s updates focus on the DELTAWAVE Nasal Pillows System, a patented and FDA‑cleared CPAP interface that REMSleep positions as a more comfortable alternative for pressure‑sensitive or non‑compliant CPAP users.
News coverage for REMSleep often highlights regulatory milestones, such as 510(k) clearance for the DELTAWAVE Nasal Pillows System and allowance of a utility patent for its nasal ventilation system by the United States Patent and Trademark Office. These announcements provide insight into the company’s progress in securing regulatory approvals and protecting its intellectual property.
Investors and industry observers can also follow commercial and distribution developments, including REMSleep’s formal agreement with 1800CPAP.com to feature the Deltawave CPAP mask system, Medicare registration approval for Deltawave, and the build‑out of independent sales representative networks. Press releases describe marketing strategies, national media plans, VA and DME outreach, and efforts to secure key distributor partnerships and clinical trial opportunities.
Another recurring theme in REMSleep news is operational and launch status updates. The company has issued shareholder letters and press releases discussing launch timelines, supply chain considerations such as medical‑grade silicone delivery and mold production, and the implementation of systems like enterprise resource planning to support inventory, quality, and sales management.
For those tracking RMSL, this news feed offers a centralized view of regulatory clearances, product launch progress, distributor interest, marketing initiatives, and SEC‑related disclosures. Bookmark this page to monitor how REMSleep advances Deltawave and its planned next‑generation CPAP interfaces in the sleep apnea device market.
Summary not available.
Summary not available.
REMSleep Holdings, Inc. (OTC PINK: RMSL) announced that the FDA requires additional testing for its 510K submission regarding product development. The company plans to initiate testing promptly. Furthermore, proceeds from the Reg A offering will support ongoing product development, expected patent applications, and inventory buildup pending 510K approval. The press release also contains forward-looking statements highlighting risks, including the potential inability to secure financing and regulatory challenges that could affect business outcomes.
REMSleep Holdings, Inc. (OTC PINK: RMSL) has announced that its submission K212087 has passed the acceptance review. The submission was found to contain all necessary elements for a substantive review, and a lead reviewer has been assigned to the case. The company plans to provide further updates as they become available.
This announcement follows the regulatory protocol and demonstrates the company's progress in its submission process, which may have implications for future developments.
REMSleep Holdings, Inc. (OTC PINK: RMSL) has filed a 510K submission for its DeltaWave CPAP pillows interface mask. The submission, numbered K212087, was received on July 6, 2021. This marks a significant step for the company in advancing its product offerings in the sleep treatment market. The DeltaWave Nasal Pillows System aims to enhance patient comfort and efficacy in CPAP therapy. The press release includes forward-looking statements that caution against placing undue reliance on future projections and highlights potential risks associated with financing, competition, and regulatory matters.
REMSleep Holdings, Inc. (OTC: RMSL) has engaged Empirical Technologies Corp to expedite its 510K submission, addressing frustrations with previous delays. This partnership aims to enhance the submission process, with ETC boasting a 100% success rate and approvals 20% to 40% quicker than industry norms. The company received a patent approval in April 2021 and is preparing to launch its marketing program post-510K clearance. Future products are in development, expected to be released more efficiently.